ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag us supreme court genetics genomics microbiology ecology disease medicine

bacteria and DNA molecules on a purple background.
Engineering the Microbiome: CRISPR Leads the Way
Mariella Bodemeier Loayza Careaga, PhD | Mar 15, 2024 | 10+ min read
Scientists have genetically modified isolated microbes for decades. Now, using CRISPR, they intend to target entire microbiomes.
An illustration of green bacteria floating above neutral-colored intestinal villi
The Inside Guide: The Gut Microbiome’s Role in Host Evolution
Catherine Offord | Jul 1, 2021 | 10+ min read
Bacteria that live in the digestive tracts of animals may influence the adaptive trajectories of their hosts.
Notebook
The Scientist Staff | Mar 30, 1997 | 7 min read
The American Medical Association (AMA), not to be outdone by the recent controversies surrounding sheep cloning, wrestled with a few ethical issues of its own earlier this month in Philadelphia. At a conference entitled "Ethics and American Medicine: History, Change, and Challenge," speakers tackled subjects such as end-of-life care and the problems of managed care and health-care rationing. The meeting’s concluding session, a roundtable discussion on medicine’s future ethical chall
Biotech Faces Evolving Patent System
Douglas Steinberg | Mar 5, 2000 | 8 min read
Like medieval alchemists, modern biologists apply intricate, esoteric protocols to lowly matter, such as bacteria and rodents. Unlike alchemists, biologists successfully transmute these creatures into gold--disease-fighting pharmaceuticals and profits accruing from them. An indispensable ingredient in this dross-to-drug process is patent protection, which preserves monopoly and attracts investment. Unfortunately, the patent system isn't as ideal a catalyst as the chimerical philosopher's stone s
Notebook
The Scientist Staff | Apr 26, 1998 | 8 min read
WHAT FOLLOWS TAMOXIFEN? Warnings accompanied recent announcements from the University of Pittsburgh-based National Surgical Adjuvant Breast and Bowel Project and the National Cancer Institute in Bethesda, Md., that tamoxifen achieved a 45 percent reduction in the incidence of breast cancer compared to women who took a placebo in the Breast Cancer Prevention Trial. The 25-year-old drug still carries the risk of serious side effects for women over 50, officials said. But the overall results were

Run a Search

ADVERTISEMENT